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Background. Female Parkinson’s disease (PD) patients seem to experience not only more severe motor complications and postural
instability but alsomore pronounced depression, anxiety, pain, and sleep disturbances.Objective.The aimof the present studywas to
evaluate the role of sex as a possible independent predictor of HRQoL in PD.Methods. In this cross-sectional study, 621 consecutive
patients treated at the University of Pe´cs were enrolled. Severity of PD symptoms was assessed by MDS-UPDRS, UDysRS, Non-
Motor Symptoms Scale, PDSS-2, Hamilton Anxiety Scale, Montgomery-Asberg Depression Rating Scale, Lille Apathy Rating
Scale, and Addenbrooke Cognitive Examination. HRQoL was assessed by PDQ-39 and EQ-5D. Multiple regression analysis was
performed to estimate the PDQ-39 and EQ-5D index values based on various clinical factors. Results. Although females received
significantly lower dosage of levodopa, they had significantly more disabling dyskinesia and worse postural instability. Anxiety,
pain, sleep disturbances, and orthostatic symptoms were more frequent among females while sexual dysfunction, apathy, and
daytime sleepiness were more severe among males. Women had worse HRQoL than men (EQ-5D index value: 0.620±0.240 versus
0.663 ± 0.229, 𝑝 = 0.025, and PDQ-39 SI: 27.1 ± 17.0 versus 23.5 ± 15.9, 𝑝 = 0.010). Based on multiple regression analysis, sex was
an independent predictor for HRQoL in PD. Conclusions. Based on our results, female sex is an independent predictor for having
worse HRQoL in PD.
1. Introduction
Recently the nonmotor symptoms (NMS) of Parkinson’s
disease (PD) have been increasingly recognized as a major
burden of the health-related quality of life (HRQoL) [1,
2]. In PD, the range of NMS can include high variety of
problems such as mood disorders (depression and anxiety),
sleep disorders, cognitive dysfunctions, dementia, autonomic
dysfunctions, apathy, and fatigue [3, 4]. These NMS are
not only common in patients with PD, but also usually
underrecognized [5]. According to some studies, at least
one NMS was reported by almost 100% of patients [6, 7],
with the most common being autonomic dysfunction, mood
disorders, and sleep problems [8, 9]. Although many NMS
are apparent and common among de novo and nontreated
PD patients, there are also some NMS that are usually
considered to be secondary to pharmacotherapy, such as
impulse control disorders (ICD) and psychosis. Moreover,
NMS have also been reported by patient surveys to be
sometimes more disabling than the motor symptoms of
tremor and bradykinesia [10]. In advanced PD, the NMS can
have a pattern of fluctuation similar to the motor symptoms
[11, 12]. Moreover, some of the PD patients state that their
nonmotor fluctuations cause a greater degree of disability and
distress than the motor fluctuations [13]. This fact has been
reinforced by recent studies demonstrating that in some cases
the NMS have higher impact on the HRQoL than the motor
symptoms do [3, 14].
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Previous studies incongruently demonstrated that sex is
an independent predictor for some NMS [15]. Female PD
patients seem to experience not onlymore severemotor com-
plications and falls but also more pronounced depression,
anxiety, pain, and sleep disturbances [16–18]. On the other
hand, males tend to have more pertinent apathetic symptoms
and sexual dysfunction [19–21]. The role of sex being an
independent predictor of HRQoL in PD is controversial.
Several studies demonstrated that female sex was associated
with poorer HRQoL. However, the role of gender was not
unambiguous even in the studies: someof these investigations
concluded that female sex was an independent negative
predictor while others stated that female sex was only a
nonindependent predictor of HRQoL in PD. In other words,
these latter investigations suggested that not the female sex
but the nonmotor symptoms associated with female sex had
a direct impact on HRQoL. Indeed, several other studies
have reported no gender difference for HRQoL in PD, at
all, but have not specifically addressed potential reasons for
this. A direct investigation of the relationship between sex
and HRQoL is still lacking in a large representative pool of
patients. In light of the aforementioned findings, the aim
of this study was to extend recent studies investigating the
association between HRQoL and disease stage in PD, motor
subtype, and gender using a large pool of well-characterized
patients.
2. Materials and Methods
2.1. Patients. In this cross-sectional study, 621 consecutive
and nonselected patients treated at the University of Pe´cs
were enrolled. All patients fulfilled theUKBrain Bank criteria
for PD [22]. Each subject gave written informed consent
in accordance with the ethical approval of the Regional
Ethical Board (3617.316-24983/KK41/2009). Each patient was
examined by a neurologist specialized in movement dis-
orders. Besides recording demographic data (age, sex, and
level of education) some disease-specific data were also
noted (age at onset; disease duration; presence of motor
complications, duration of fluctuation in years; type of PD
being either tremor dominant, rigid-akinetic, or mixed type;
and antiparkinsonian medication). Patients were evaluated
in ON state while receiving their usual antiparkinsonian
and othermedications and subsequently levodopa equivalent
dosage (LED) calculations were performed [23].
2.2. Assessment of Motor Symptoms. Severity of PD-related
symptoms was globally assessed by the Hungarian validated
version of the MDS-UPDRS [24, 25]. The recently published
MDS-UPDRS is a validated scale to assess nonmotor (nM-
EDL, Part I) and motor-experiences of daily living (M-
EDL, Part II), motor examination (ME, Part III), and motor
complications (MC, Part IV) [25]. As a part of the MDS-
UPDRS, the Hoehn-Yahr Scale was also taken to detect the
overall severity of PD. Based on previous reports, we analyzed
separately items 3.12 “Postural instability” and 2.12 “Walking
and balance” ofMDS-UPDRS. Additionally, the axial items of
MDS-UPDRSMEwere also assessed following themethod of
Kotagal et al. [26] by summing items 3.1 “Speech,” 3.9 “Arising
from a Chair,” 3.10 “Gait,” 3.12 “Postural Stability,” and 3.13
“Posture.”
Dyskinesia was measured by the Hungarian validated
version of Unified Dyskinesia Rating Scale [27, 28]. We also
asked our patients to keep a patient diary measuring ON
state without dyskinesia, ON state with slight nondisturbing
dyskinesia, ON state with severe dyskinesia, OFF state, and
sleep periods for at least 3 days prior or immediately after the
examination [29, 30].
2.3. Assessment of Nonmotor Symptoms. The nM-EDL part
of the MDS-UPDRS has items evaluating the presence
and severity of 13 NMS including depression, anxiety, apa-
thy, dopamine-dysregulation, cognitive impairment, fatigue,
pain, hallucinations, urinary problems, sexual problems,
orthostatic problems, nighttime sleep problems, and daytime
sleepiness.These items are also intended to serve as screening
tools for the presence of these nonmotor symptoms [31].
To assess nonmotor symptoms globally, the Non-Motor
Symptoms Scale (NMSS) [32] was also included. This scale
is obtained by trained professionals and capable of simulta-
neously capturing the severity and frequency of 30 nonmotor
symptoms typical for PD. These NMSS items can group nine
domains including sleep, cardiovascular, cognitive, mood,
hallucinatory, gastrointestinal, urinary, sexual, and miscella-
neous problems.
Presence and severity of sleep disturbances were specifi-
callymeasured by theHungarian validated version of PDSS-2
[33, 34]. The threshold indicating sleep problems is 11 points
for the Hungarian version of PDSS-2 [35]. In the meantime,
daytime sleepiness was assessed by the Epworth Sleepiness
Scale [36] with the cutoff value of 8 points [37]. Depression,
anxiety, and apathy were assessed by the Hungarian validated
versions of the Montgomery Depression Scale (MADRS)
[38], the Hamilton Anxiety Scale (HAM-A) [39], and the
Lille Apathy Scale (LARS) [40]. Cognitive performance was
examined by the Hungarian validated versions of Mini-
Mental Status Examination (MMSE) [41], Montreal Cogni-
tive Assessment (MoCA) [42], Mattis Dementia Rating Scale
(MDRS) [41], and Addenbrooke Cognitive Examination
(ACE) [41, 43]. Presence of dementia (major neurocognitive
disorder) was defined as either achieving ≤125 points on
the Hungarian validated version of the Mattis Dementia
Rating Scale [41, 43] and/or ≤22 points on the Montreal
Cognitive Assessment [43] and/or fulfilling the criteria of
dementia according to theDSM-5 [44]. Presence and severity
of impulse control disorders (ICD)were assessed by the ques-
tionnaire for impulsive-compulsive disorders in Parkinson’s
disease (QUIP) [45].The global functioning was evaluated by
the Schwab & England Scale (SES) [38, 46].
Health-related quality of life (HRQoL) was measured by
the Hungarian validated version of the disease-specific PDQ-
39 Summary Index (PDQ-39 SI) [47] and the nondisease
specific EuroQol instrument (EQ-5D index value) [48, 49].
Generally, higher scores on PDQ-39 SI and smaller index
values on the EQ-5D represent worse HRQoL states.
The whole assessment required a total of approximately
5-6 hours to complete. To reduce the burden of patients, the
clinical assessments were performed on three consecutive
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days. Typically on Day 1 both the ME part of MDS-UPDRS
and UDysRS were taken. On Day 2, the patients under-
went the neurocognitive evaluation by psychologists. All the
patient reported questionnaires had to be completed by Day
3 (including the PD diary).
2.4. Statistical Analysis. All statistical analyses were carried
out using the IBMSPSS software package (version 22.0.1, IBM
Inc., Armonk, NY, USA). Because data from these scales fol-
lowed the normal distribution,mean and standard deviations
(SD) were calculated. For group comparisons, independent
samples 𝑡-tests were applied. Evaluating significant differ-
ences in single items of MDS-UPDRS, both independent
samples 𝑡- and Mann-Whitney tests were utilized because
they were ordinal variables. For categorical variables (e.g.,
having or not having a symptom) Chi-square tests were used.
Statistical significance level was set at 5%.
Amultiple regressionmodelling using a stepwise method
(criteria: probability of 𝐹 to enter ≤0.050 and probability
of 𝐹 to remove ≥0.100) was initiated to predict the PDQ-
39 SI from various clinical variables including sex, age,
age at disease onset, years of education, disease duration,
fluctuations in years, handedness, disease-type, ACE, MDRS,
MADRS, levodopa dosage (measured in LED), DALED, total
LED, LARS, ON time without dyskinesia, ON time with
slight dyskinesia, ON time with severe dyskinesia, OFF time,
PICD, PDSS-2, ESS, HAS, UDysRS, M-EDL part of MDS-
UPDRS, ME part of MDS-UPDRS, and MC part of MDS-
UPDRS. Subsequently, another multiple regression analysis
was performed to predict the EQ-5D index values from the
same variables using a stepwise method.
3. Results
3.1. Demographic and PD-Related Clinical Data. The subject
population consisted of 621 consecutive PD patients (361
males, age: 66.9 ± 9.2 years, disease duration: 7.6 ± 6.1 years).
Two-hundred and forty-seven patients had rigid-akinetic,
194 had tremor dominant, and 180 had mixed type of PD.
In the examined sample, 234 patients (37.7%) had motor
fluctuations with the average duration of 6.5 ± 4.2 years.
Only 127 (20.5%) patients had either fulltime or part-time
job at the time of the exam. Handedness, dominant side, and
Hoehn-Yahr staging are demonstrated in Table 1, whereas
the medication usage and levodopa equivalent dosages are
shown in Table 2. Levodopa treatment was applied in 454
(73.1%), dopamine-agonists in 320 (51.5%), and catechol-
O-methyl-transferase inhibitors in 223 (35.9%) patients. In
the studied population 98 (15.8%) patients underwent deep
brain stimulator implantation with electrodes targeted into
the subthalamic nuclei bilaterally.
3.2. Motor Symptoms of PD. Although age at PD onset,
disease duration, education years, and severity of motor
symptoms (MDS-UPDRS Motor Examination) were compa-
rable between the males and females, men received signifi-
cantly higher dosage of levodopa (551.4 ± 413.3mg versus
423.6 ± 386.3mg, 𝑝 = 0.001, Table 2). Based on the M-EDL
MDS-UPDRS, the overall motor symptoms were associated
Table 1: Basic characteristics of the study population (𝑛 = 621).
Mean SD Count Percentage
Age at PD onset (years) 59.4 11.6
Age at PD
onset (years)
<36 years 14 2.3%
36–45 years 63 10.1%
46–55 years 144 23.2%
56–65 years 205 33.0%
66–75 years 144 23.2%
>75 years 51 8.2%
Disease duration (years) 7.6 6.1
Disease
duration
(years)
0–5 years 241 38.8%
6–10 years 186 30.0%
11–15 years 124 20.0%
>15 years 70 11.3%
Gender Male 361 58.1%
Female 260 41.9%
Handedness Right handed 589 94.8%
Left handed 32 5.2%
Dominant
side
Right dominance 356 57.3%
Left dominance 265 42.7%
Education (years) 12.3 3.3
PD type
Rigid-akinetic 247 39.8%
Tremor dominant 194 31.2%
Mixed type 180 29.0%
Hoehn-Yahr
stage
1 29 4.7%
2 315 50.7%
3 164 26.4%
4 94 15.1%
5 19 3.1%
Fluctuation (years) 6.5 4.2
Presence of
fluctuations
No 387 62.3%
Yes 234 37.7%
Working
status
Full time job 54 8.7%
Part-time job 73 11.7%
No job due to
illness 236 37.9%
No job unrelated to
illness 258 41.7%
Housework
status
Does household
work
independently
347 55.9%
With others’ help
does household
work
146 23.5%
Fully
self-dependent but
does not perform
housework
67 10.8%
Partly
self-dependent 43 6.9%
Requires full
support 18 2.9%
SD: standard deviation.
with similar disabilities in both sexes. Although the axial
scores on MDS-UPDRS ME were comparable, females had
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Table 2: Impact of gender on various demographic factors, medication usage, and motor- and nonmotor symptoms of Parkinson’s disease.
Gender
𝑝 valueMale (𝑛 = 361) Female (𝑚 = 260)
Mean or
count
SD or
percentage
Mean or
count
SD or
percentage
Demographic
Age at PD onset (years) 59.0 11.9 60.0 11.0 0.265
Disease duration (years) 7.7 6.1 7.5 6.2 0.736
Education (years) 12.8 3.1 11.5 3.4 0.112
Medication
Levodopa dosage (LED in mg) 551.4 413.3 423.6 386.3 <0.001
Dopamine agonist dosage (LED in mg) 174.4 230.8 160.6 224.4 0.455
Anti-Parkinson’s medication (LED in mg) 725.8 594.8 584.7 424.5 0.001
MDS-UPDRS
MDS-UPDRS nM-EDL 13.8 7.5 15.1 7.9 0.034
MDS-UPDRS M-EDL 15.4 9.2 14.9 9.2 0.536
MDS-UPDRS 2.12 Walking 1.4 1.1 1.6 1.2 0.009∗
MDS-UPDRS ME 37.9 17.4 37.5 17.8 0.801
MDS-UPDRS ME axial score 6.0 3.8 6.3 4.1 0.131
MDS-UPDRS 3.12 Postural instability 1.1 1.3 1.5 1.4 0.001∗
MDS-UPDRS MC 4.7 3.8 4.8 4.2 0.752
MDS-UPDRS Total score 71.9 31.2 72.2 33.3 0.901
UDysRS
UDysRS Part1 ON Dyskinesia 12.6 9.3 15.5 9.3 0.004
UDysRS Part2 OFF Dyskinesia 6.5 4.6 6.8 4.5 0.605
UDysRS Part3 Impairment 6.4 5.2 7.9 5.6 0.008
UDysRS Part4 Disability 4.3 3.3 5.0 3.3 0.033
UDysRS Historic subscore 19.2 11.0 22.4 11.7 0.010
UDysRS Objective subscore 10.7 8.2 13.0 8.6 0.011
UDysRS Total score 30.1 17.4 35.5 18.6 0.006
Patient diary
ON without dyskinesia (hours) 8.9 6.2 8.9 6.3 0.897
ON with slight Dyskinesia (hours) 2.0 3.5 1.8 2.6 0.130
ON with severe dyskinesia (hours) 0.3 1.3 0.3 1.3 0.911
OFF time (hours) 4.2 5.7 5.0 6.0 0.212
Awake time (hours) 15.4 2.2 15.5 2.1 0.931
Daytime sleep time (hours) 0.7 1.2 0.5 0.8 0.005
Nighttime sleeping time (hours) 7.8 1.8 8.1 1.9 0.171
Sleep
Presence of sleep problems 229 63.4% 189 72.7% 0.034
PDSS-2 Total score 16.3 11.2 18.3 11.1 0.027
Presence of daytime sleepiness 142 39.3% 70 26.9% 0.001
Epworth Sleepiness Scale 7.8 5.0 6.4 4.4 0.000
Affective
Presence of affective problems 276 76.5% 221 85.0% 0.036
MADRS Total score 11.8 8.0 14.2 7.6 0.003
HAM-A Total score 12.5 6.0 16.0 6.9 0.001
Neurocognitive
ACE Total score 82.1 11.0 81.1 11.4 0.368
MMSE Total score 27.3 2.8 27.3 2.9 0.911
MoCA Total score 23.6 3.9 23.6 4.3 0.984
MDRS Total score 133.3 16.2 132.2 21.5 0.587
Mild neurocognitive disorder 78 21.6% 49 18.8% 0.230
Major neurocognitive disorder 47 13.0% 33 12.7 0.503
LARS total score −20.4 10.8 −22.8 8.9 0.004
NMSS
NMSS cardiovascular 2.9 3.8 3.8 4.1 0.004
NMSS sleep problems 13.0 9.6 14.3 9.9 0.108
NMSS mood problems 12.4 14.3 15.3 12.3 0.016
NMSS hallucinations 1.5 4.1 1.5 3.3 0.976
NMSS memory problems 6.2 7.1 6.4 7.1 0.686
NMSS gastrointestinal problems 4.9 6.0 4.3 5.6 0.179
NMSS urinary problems 10.0 9.1 11.2 10.2 0.130
NMSS sexual problems 2.9 5.8 1.8 5.2 0.022
NMSS miscellaneous problems 3.8 4.8 5.5 6.3 0.000
NMSS total score 57.4 41.2 64.1 41.1 0.045
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Table 2: Continued.
Gender
𝑝 valueMale (𝑛 = 361) Female (𝑚 = 260)
Mean or
count
SD or
percentage
Mean or
count
SD or
percentage
Health-related quality of life
EQ-5D VAS 64.8 20.1 62.4 20.1 0.135
EQ-5D index value 0.663 0.229 0.620 0.240 0.026
PDQ-39 mobility 31.0 27.9 39.6 27.7 0.000
PDQ-39 ADL 29.3 25.0 26.8 24.8 0.221
PDQ-39 emotional well being 25.0 20.7 34.9 24.9 0.000
PDQ-39 stigma 23.2 24.5 25.1 27.3 0.370
PDQ-39 social support 11.0 15.4 13.8 16.8 0.038
PDQ-39 cognition 21.5 19.3 21.0 16.9 0.751
PDQ-39 communication 20.1 20.6 16.4 18.7 0.022
PDQ-39 bodily discomfort 27.3 20.9 39.2 24.8 0.000
PDQ-39 summary index 23.5 15.9 27.1 17.0 0.010
SES total score 75.0 16.2 74.1 19.4 0.636
For statistical analysis unpaired 𝑡-test was applied. In cases of items marked with ∗additionally Mann-Whitney test was also applied and yielded statistically
significant differences.
Abbreviations: ACE = Addenbrooke Cognitive Examination; BDI = Beck Depression Inventory; EQ-5D = EuroQol Instrument 5 layer version; EQ-5D VAS =
EuroQol Instrument Visual Analogue Scale; ESS = Epworth Sleepiness Scale; HAM-A = Hamilton Anxiety Scale; LARS = Lille Apathy Rating Scale; LED =
levodopa-equivalent dosage;MADRS =Montgomery-Asberg Depression Rating Scale;MDRS =Mattis Dementia Rating Scale;MDS-UPDRS =TheMovement
Disorder Society-sponsored Unified Parkinson’s Disease Rating Scale; MDS-UPDRS MC = Motor Complication part of MDS-UPDRS; MDS-UPDRS ME =
Motor Examination part of MDS-UPDRS; M-EDL MDS-UPDRS = Motor-Experiences of Daily Living part of MDS-UPDRS; MMSE = Mini-Mental Status
Examination; nM-EDL MDS-UPDRS = Non-Motor-Experiences of Daily Living part of MDS-UPDRS; MoCA = Montreal Cognitive Assessment; NMSS =
Non-motor Symptoms Scale; PAS = Parkinson’s Disease Anxiety Scale; PDQ-39 = Parkinson’s Disease Questionnaire; PDSS-2 = Parkinson’s Disease Sleep Scale
2nd version; UDysRS = Unified Dyskinesia Rating Scale.
significantly worse postural instability (item 3.12) and gait-
related disabilities (item 2.12).
In the examined population, 144 males (39.9%) and 90
females (34.6%) had fluctuations (𝑝 = 0.181, Chi-square
test). Despite of receiving less dopaminergic medication,
women had significantly worse dyskinesia compared to men
(UDysRS total score: 35.5 ± 18.6 versus 30.1 ± 17.4 points,
resp., 𝑝 = 0.006, Table 2). However, the analysis of the patient
diaries revealed that both sexes had comparable ON andOFF
time.The only statistically significant difference was the time
of daytime sleep (males: 0.7±1.2hours versus females: 0.5±0.8
hours, 𝑝 = 0.005).
3.3. Nonmotor Symptoms of PD. In our study cohort only
6 patients (0.9%) did not report any NMS, at all. Based on
the 13 screening items of nM-EDL part of MDS-UPDRS, our
patients had an average of 8.08±2.78NMS symptoms. Female
patients had more severe nonmotor symptoms in general.
This finding is congruently supported by the nM-EDL part of
MDS-UPDRS (15.1 ± 7.9 versus 13.8 ± 7.5 points, 𝑝 = 0.034,
Table 2) and NMSS scores (64.1 ± 41.1 versus 57.4 ± 41.2
points, 𝑝 = 0.045, Table 2).
3.3.1. Affective Problems. Among female PD patients the anx-
iety was not only significantly more frequent (85.0% versus
76.5%,𝑝 = 0.005), but alsomore severe (HAM-A score: 16.0±
6.9 versus 12.5 ± 6.0, 𝑝 = 0.001). Although the prevalence of
depressionwas comparable between both sexes (76.2% versus
73.7%, 𝑝 = 0.386), the severity of depression was worse in
women (MADRS score: 14.2±7.6 versus 11.8±8.0,𝑝 = 0.003)
(Table 2). Similarly, the “Mood problems” section of NMSS
demonstrated more severe affective problems in the female
individuals (15.3±12.3 versus 12.4±14.3,𝑝 = 0.016) (Table 2).
3.3.2. Sleep-Related Problems. Based on the Hungarian val-
idated threshold values for PDSS-2, 72.7% of females and
63.4% of males reported sleep-related problems (Chi-square
test, 𝑝 = 0.034). Although the female PD patients had
more severe nighttime sleep disturbances (measured by the
total score of PDSS-2), daytime sleepiness wasmore common
(39.3% versus 26.9%, 𝑝 = 0.001) and more severe among
males (Table 2).
3.3.3. Cardiovascular and Orthostatic Problems. Based on the
screening item of MDS-UPDRS (1.12 orthostatic symptoms)
and the “Cardiovascular” section of NMSS, female patients
had more often (71.5% versus 62.6%, Chi-square test, 𝑝 =
0.023) and more severe orthostatic and cardiovascular prob-
lems than males (𝑝 = 0.004, Table 2).
3.3.4. Sexual Problems. Male patients had more frequent
(31.6% versus 18.1%, 𝑝 < 0.001, Chi-square test) and more
severe sexual problems than females (2.9±5.8 versus 1.8±5.2,
𝑝 = 0.022, Table 2).
3.3.5. Pain. Based on the screening item ofMDS-UPDRS (1.9
Pain) and the item 27 of NMSS (Pain), women had more
frequent (76.5% versus 67.3%, 𝑝 = 0.014, Chi-square test)
and more severe (4.8 ± 3.7 versus 2.1 ± 3.1, 𝑝 < 0.001) pain
sensations than men.
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Table 3: Impact of gender on impulse control disorders associated with Parkinson’s disease.
Sex
𝑝 value (chi-test)Male Female
Count Percentage Count Percentage
Presence of any ICD No ICD 31 8.6% 22 8.5% 0.850
Yes ICD 78 21.6% 52 20.0%
Punding No 307 85.0% 223 85.8% 0.637
Yes 54 15.0% 37 14.2%
Compulsive eating No 321 88.9% 228 87.7% 0.637
Yes 40 11.1% 32 12.3%
Hypersexuality No 343 95.0% 260 100.0% 0.000
Yes 18 5.0% 0 0.0%
Pathological gambling No 338 93.6% 251 96.5% 0.106
Yes 23 6.4% 9 3.5%
Compulsive buying No 338 93.6% 212 81.5% 0.000
Yes 23 6.4% 48 18.5%
ICD: impulse control disorder.
3.3.6. Apathy. Although the prevalence of apathywas compa-
rable (18.5% versus 21.9%, Chi-square test, 𝑝 = 0.279), males
hadmore severe apathetic symptomsmeasured by LARS than
females (−20.4 ± 10.8 versus −22.8 ± 8.9, 𝑝 = 0.004).
3.3.7. Cognition. We could not demonstrate any differences
in cognition either by NMSS or specific neurocognitive
screening tests (MMSE, MoCA, ACE, and MDRS) (Table 2).
3.3.8. Other NMS Problems. Both sexes had similarly fre-
quent and severe urinary, gastrointestinal, and hallucinatory
problems. Based on MDS-UPDRS nM-EDL, we could not
find any differences in the prevalence and the degree of
fatigue, either.
3.4. Impulse Control Disorders in PD. Based on the analysis
of QUIP, 21.6% of male and 20.0% of female PD patients
had any type and any degree of ICD problems (𝑝 =
0.850, Table 3). The prevalence and severity of pathological
gambling, compulsive eating, and punding were similar in
both sexes. However, men hadmore often hypersexuality (5%
versus 0%, 𝑝 < 0.001) and women had more frequent and
severe compulsive buying (18.5% versus 6.4%, 𝑝 < 0.001).
3.5.HRQoL. Althoughbothmale and female PDpatients had
similar everyday functioning measured by the SES (75.0 ±
16.2 versus 74.1 ± 19.4 points, 𝑝 = 0.636, Table 2), female
patients had worse HRQoL than males (EQ-5D index value:
0.620± 0.240 versus 0.663± 0.229, 𝑝 = 0.026 and PDQ-39 SI:
27.1 ± 17.0 versus 23.5 ± 15.9, 𝑝 = 0.010). Out of the PDQ-
39 components, “Mobility,” “Emotional well-being,” “Social
support,” and “Bodily discomfort” had higher impairment in
women, whereas the section of “Communication” was worse
in men.
3.6. Determinants of HRQoL in PD. Multiple regression
analysis was performed to estimate the PDQ-39 SI based on
various clinical factors. Due to collinearity, age of disease
onset, MDRS, and MMSE scores were excluded from the
regression analysis (tolerance < 0.001). The data met the
assumption of independent errors (Durbin-Watson value =
1.911). Using a stepwise method it was found that M-EDL
part of MDS-UPDRS (importance = 0,53; 𝛽 = 0.883, 𝑝 <
0.001), PDSS-2 total score (importance = 0.12; 𝛽 = 0.260,
𝑝 < 0.001), MADRS total score (importance = 0.09; 𝛽 =
0.423, 𝑝 = 0.002), sex (coded as 1 = males and 2 = females,
importance = 0.06; 𝛽 = −3.389, 𝑝 = 0.010), ME part ofMDS-
UPDRS (importance = 0,05; 𝛽 = −0.134, 𝑝 = 0.012), SES
(importance = 0.04; 𝛽 = −0.124, 𝑝 = 0.017), UDysRS total
score (importance = 0.03; 𝛽 = 0.166, 𝑝 = 0.013), HAM-A
total score (importance = 0.03; 𝛽 = 0.258, 𝑝 = 0.019), ACE
total score (importance = 0.03; 𝛽 = −0.118, 𝑝 = 0.027), QUIP
total score (importance = 0.02; 𝛽 = 0.667, 𝑝 = 0.029), and
ESS total score (importance = 0.02; 𝛽 = 0.186, 𝑝 = 0.038)
explain the highest significant amount of variance in the value
of the PDQ-SI score (intercept = 22.433, 𝐹(9, 593) = 120.400,
𝑝 < 0.001, 𝑅2adjusted = 0.741). The other examined variables
did not significantly contribute to the model.
For estimating the EQ-5D index value SES (importance
= 0.47; 𝛽 = 0.006, 𝑝 < 0.001), M-EDL part of MDS-
UPDRS (importance = 0.33; 𝛽 = −0.010, 𝑝 < 0.001), PDSS-
2 total score (importance = 0.11; 𝛽 = −0.004, 𝑝 = 0.013),
ME part of MDS-UPDRS (importance = 0.04; 𝛽 = −0.002,
𝑝 = 0.012), UDysRS total score (importance = 0.03; 𝛽 =
−0.162, 𝑝 = 0.016), QUIP total score (importance = 0.03;
𝛽 = −0.011, 𝑝 = 0.018), MADRS total score (importance
= 0.02; 𝛽 = −0.002, 𝑝 = 0.038), and sex (coded as 1 =
males and 2 = females, importance = 0.04; 𝛽 = 0.032, 𝑝 =
0.010) contributed significantly to a model (intercept = 0.318,
𝐹(4, 309) = 46, 547, 𝑝 < 0.001, 𝑅2adjusted = 0.608).
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4. Discussion
Although the sexual differences in PD have been previously
recognized, they are poorly understood. The aim of the
present study was evaluate the impact of sex on the pres-
ence and severity on various PD-related symptoms and the
HRQoL.
4.1. Motor Symptoms and Motor Complications. First, we
were unable to detect any sex-related differences in the
major demographic data (e.g., age at disease onset, disease
duration, and education level) and overall motor perfor-
mance. Although females received significantly lower dose
of levodopa, the severity of motor symptoms (MDS-UPDRS
ME) and the disability related to motor symptoms (MDS-
UPDRSM-EDL) were comparable between both sexes.These
findings are congruent with the results of several previous
studies [17, 50, 51].
Despite of the lower overall levodopa dosage, women had
worse dyskinesia measured by UDysRS. This finding is also
in agreement with the literature [52–54].
Because previous studies demonstrated that female sex
is associated with significantly worse postural instability
and more frequent falls [55–57], therefore, we separately
analyzed items 3.12 “Postural instability” and 2.12 “Walking
and balance” of MDS-UPDRS. In these two items, women
had significantly worse scores (justified by both 𝑡- andMann-
Whitney tests, Table 2). Item 2.12 emphasizes the need for
assistance rather than the consequence (falls) thatwill depend
on availability of help [25]. However, together with item
3.12 it reflects the postural instability, gait difficulties, and
the tendency of falls. Because other items of MDS-UPDRS
M-EDL and ME did not differ between man and women
(data not shown), we can conclude that the worse postural
instability and tendency of falls are independently more
pronounced in females.
4.2. Nonmotor Symptoms. Based on our data, more than
99% of the patients had at least one NMS with an average
number of 8 out of the 13 items screened by theMDS-UPDRS.
The most prevalent NMS problems were fatigue, anxiety,
depression, daytime sleepiness, and pain. These findings are
congruent with the literature [58, 59].
Consistent with the previously published data, we
demonstrated that anxiety [4, 16, 17], pain [4, 17, 18], noc-
turnal sleep difficulties, and orthostatic symptoms were more
frequent among female PD patients while the prevalence of
sexual dysfunction [4, 20, 21] and daytime sleepiness were
more common among males [4, 60]. Although depression
was similarly common among both sexes [9], the depressive
symptoms were more severe in females [61, 62]. Contrarily,
the apathetic symptoms were more pronounced in males
despite of their similar occurrence in both sexes. In our
cohort, we could not find any sex-related differences in the
frequency and severity of fatigue. In the literature there are
inconsistent data available, some supporting [4, 52, 63] and
others disagreeing [64] with a possible link between sex and
fatigue.
4.3. Impulse Control Disorders. In agreement with some
studies [65, 66] and in opposition to other papers [67, 68],
we did not find significant differences in the prevalence
of global ICD symptoms between both sexes. Though total
ICD frequency was similar for men and women, there were
notable sex differences in the frequency of specific ICDs,
with hypersexuality more common in males and compulsive
buying and binge eating were more prevalent in women.
These sex-related differences were previously reported [69].
4.4. Determinants of HRQoL in PD. The role of sex on
HRQoL in PD is highly controversial. Indeed, some publica-
tions did not demonstrate any differences inHRQoL between
males and females [3, 15, 57, 70–72]. These studies were per-
formed in distinct areas (e.g., Australia [15], Eastern-Europe
[3, 57, 73], Northern-Europe [74, 75], Western-Europe [72,
76], and America [77]) and utilized heterogeneous HRQoL
questionnaires (e.g., PDQ-39 [3, 15], EQ-5D [73], MOS Short
Form 36, SF-36 [77], and Nottingham Health Profile [74]).
In another group of reports, the observed differences
between females and males with respect to HRQoL were not
solely contributed to the sex because regression analyses did
not reveal the independent role of sex. Klepac et al. examined
111 consecutive Croatian PD patients, but they failed to prove
the role of sex (multiple regression coefficient: 37.961, 𝑝 =
0.051) in determining HRQoL. Marras et al. demonstrated
that the presence and severity of dyskinesia, but not the sex
alone, predicted the HRQoL (EQ-5D) in the case of 182 PD
patients enrolled into a randomized trial (CALM-PD) and
completed the 4-year follow-up examination [78].
A third group of investigations did not include the “sex”
as a possible predictor in their statistical analyses [1, 79–81].
Morimoto et al. examined 1200 Japanese PD patients by SF-
36 questionnaire; however, they did not enter the sex as a
covariate into their regression models [80]. Similarly, Qin
et al. examined the HRQoL in 391 Chinese patients with
early Parkinson’s disease by SF-36 without entering the sex as
a possible independent factor [81]. Although Santos-Garc´ıa
and de la Fuente-Ferna´ndez aimed to investigate the role of
NMS on the health-related and the perceived quality of life
on the cohort of 150 nonselected PD patients, they did not
analyze the independent role of sex either [1].
A fourth group of papers demonstrated that females
had worse HRQoL than males and sex was an independent
predictor for HRQoL [82–88].These studies included diverse
ethnical and cultural populations (e.g., Asia [82, 83, 85],
Africa [88], Eastern-Europe [87], and Western-Europe [84,
86]).
We might assume heterogeneous factors behind these
diverse outcomes of the aforementioned studies. One of
the most important issues might be the differences in the
applied outcome measures. While the majority of the exami-
nations applied disease-specific instruments (PDQ-39, PDQ-
8 or PDQL), others utilized only generic tests (SF-36, EQ-
5D, or Nottingham Health Profile). Because the construct,
precision, and response of these scales are highly different,
the uniform and comparable interpretation of their outcomes
is difficult. Another problem might be the differences in
sociocultural profiles of the enrolled individuals. Because
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the perceived HRQoL highly depends on cultural and social
attitudes of patients, some PD-related symptoms are likely
to be differently interpreted by Western-European, Eastern-
European, African, Asian, American, and Oceanian individ-
uals. The disability, the reduced working capability and self-
dependence associated with PD are differently understood
and accepted by many cultures and societies. For example,
while the HRQoL of patients with PD inWestern countries is
predominately affected by clinical parameters, social factors
play much more pronounced role in the Eastern countries
[73].
Another key factor might be the pronounced differences
in the size of enrolled patient populations.While themajority
of studies having negative conclusion on the independent role
of sex had the typical sample size of 100–300 patients, all the
larger studies (>400 patients) had positive outcome. Of note,
in some negative European studies, the 𝑝 values were indeed
close to the level of statistical significance (e.g., Kadastik-
Eerme et al. [3], 𝑝 = 0.06, and Klepac et al. [89], 𝑝 = 0.051),
which might suggest the possibility of statistical underpower
in the background (Type II error).
Our study clearly demonstrates on a large pool of patients
that sex is an independent predictor of HRQoL in PD. This
finding was assured by the utilization of both disease-specific
and general HRQoL instruments. Based on the multivariate
stepwise regression analysis we could show that female sex
is independently associated with poorer HRQoL despite
the sex-dependent profile of NMS. One of the assumptions
behind this phenomenonmight be the diverse effects of estro-
gen. Estrogen has numerous effects on dopamine neurotrans-
mission inhibiting dopamine uptake and altering dopamine
synthesis and release [90]. These effects are extremely com-
plex and dependent on many factors, including the nature of
the estrogen exposure (e.g., exposure to normal fluctuations
in estrogen levels throughout the menstrual cycle, exposure
to the estrogen-deficient state of menopause, or exposure
through various estrogen treatment regimens). Basic research
in experimental animals indicates the neuroprotective roles
of estrogen over various forms of injury [91] and one of
its consequences might be the greater incidence of PD in
men than in women. However, sex-related differences are
also identified in response to treatment of PD; for example,
women have greater levodopa bioavailability [92].This might
contribute to our observation that females have comparable
overall severity of motor symptoms and more pronounced
dyskinesia despite of lower levodopa equivalent dosages [93].
4.5. Limitations of the Study. Although we endeavored to
strategize this study with precision, the authors are aware
of some potential limitations. One limitation may be that
our study had a monocenter design instead of a more
favorable multicenter one. In the role of a simultaneously
primary and a tertiary center, the University of Pe´cs has
both noncomplicatedPDpatients from the surrounding areas
and the advanced PD patients from the nationwide primary
and secondary centers. Therefore, the pool of patients are
likely different from those of typical primary or secondary
centers. However, in the role of a tertiary center, consider
our advantage: relatively a large portion of severe (HYS 4&5)
patients were also included in our study. This may have
contributed to a relatively high percentage of the population
featuring advanced PD and or minor/major neurocognitive
disorders.
Additionally, we appliedmore recent and slightly different
test batteries than the majority of older studies utilized.
Instead of the UPDRS and PDSS, we have applied the
more advantageous MDS-UPDRS and PDSS-2. Therefore,
the comparison of our results with those of older studies
utilizing the preceding test batteries is not straightforward
and needs careful interpretation.
5. Conclusions
Based on our results, female sex is an independent predictor
for having worse health-related quality of life in Parkinson’s
disease. Because the main intention of PD-care is to improve
not only the symptoms of PD but also the quality of life
of patients, the recognition of female sex as a negative
predictor of HRQoL is of the utmost importance. In clinical
setup, therefore, additional attention should be paid to female
patients to achieve the best obtainable health status and
HRQoL. Besides, further studies are needed to reveal the
pathophysiological differences between female and male
patients.
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